At a glance
- Originator Fujisawa
- Class Anti-inflammatories
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 22 May 2001 No-Development-Reported for Inflammation in Japan (Unknown route)
- 22 May 2001 No-Development-Reported for Pain in Japan (PO)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa